Compare RAPP & ABR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RAPP | ABR |
|---|---|---|
| Founded | 2022 | 2003 |
| Country | United States | United States |
| Employees | N/A | 653 |
| Industry | | Real Estate Investment Trusts |
| Sector | | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 2024 | N/A |
| Metric | RAPP | ABR |
|---|---|---|
| Price | $41.85 | $5.01 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 5 |
| Target Price | ★ $48.50 | $9.90 |
| AVG Volume (30 Days) | 431.1K | ★ 3.8M |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | ★ 15.42% |
| EPS Growth | ★ 24.34 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $9.29 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.64 | $4.86 |
| 52 Week High | $43.76 | $12.58 |
| Indicator | RAPP | ABR |
|---|---|---|
| Relative Strength Index (RSI) | 59.76 | 40.61 |
| Support Level | $33.54 | $4.99 |
| Resistance Level | $43.76 | $5.49 |
| Average True Range (ATR) | 2.88 | 0.20 |
| MACD | 0.15 | 0.02 |
| Stochastic Oscillator | 66.30 | 25.60 |
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
Arbor Realty Trust Inc is a specialized real estate finance company. It invests in a diversified portfolio of structured finance assets in the multifamily, SFR, and commercial real estate markets, consisting of bridge and mezzanine loans, including junior participating interests in first mortgages, preferred, and direct equity. In addition, it may also directly acquire real property and invest in real estate-related notes and certain mortgage-related securities. The company has two business segments, Structured Business and Agency Business. It generates a majority of its revenue from the Structured Business Segment.